Combinatorial therapy of sirolimus and heparin by nanocarrier inhibits restenosis after balloon angioplasty ex vivo

Nanomedicine (Lond). 2020 May;15(12):1205-1220. doi: 10.2217/nnm-2020-0028. Epub 2020 Apr 28.

Abstract

Aim: To develop poly(lactide-co-glycolide)-graft-polyethylenimine (PgP) as a dual drug-delivery carrier for sirolimus (SR) and heparin (Hep) to inhibit restenosis after balloon angioplasty. Materials & methods: SR was loaded in the hydrophobic core and negatively charged Hep complexed with the positively charged hydrophilic shell of PgP. SR- and Hep-loaded PgP was tested on rat aortic smooth muscle cells in vitro and injured porcine coronary arteries after balloon angioplasty ex vivo. Results & conclusion: SR and Hep loading efficiency in PgP were approximately 37 and 82%, respectively. SR- and Hep-loaded PgP treatment decreased smooth muscle cell proliferation up to 14 days post-treatment and decreased proliferation, collagen deposition and neointimal thickness and increased patency in porcine coronary arteries after balloon angioplasty ex vivo.

Keywords: balloon angioplasty; cationic polymeric micelle nanoparticle; combination therapy; drug-eluting balloon; drug-eluting stents; ex vivo; heparin; nanotechnology; restenosis; sirolimus.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angioplasty, Balloon*
  • Angioplasty, Balloon, Coronary*
  • Animals
  • Coronary Restenosis* / prevention & control
  • Heparin
  • Neointima
  • Rats
  • Sirolimus
  • Stents
  • Swine

Substances

  • Heparin
  • Sirolimus